Advertisement
UK markets close in 6 hours 48 minutes

  • FTSE 100

    8,093.32
    +52.94 (+0.66%)
     

  • FTSE 250

    19,702.49
    -16.88 (-0.09%)
     

  • AIM

    754.76
    +0.07 (+0.01%)
     

  • GBP/EUR

    1.1670
    +0.0025 (+0.22%)
     

  • GBP/USD

    1.2519
    +0.0056 (+0.45%)
     

  • Bitcoin GBP

    50,948.22
    -2,229.52 (-4.19%)
     

  • CMC Crypto 200

    1,363.05
    -19.53 (-1.41%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.12
    +0.31 (+0.37%)
     

  • GOLD FUTURES

    2,338.40
    0.00 (0.00%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    18,006.78
    -81.92 (-0.45%)
     

  • CAC 40

    8,059.64
    -32.22 (-0.40%)
     
Property:

How to sell your home

Top tips from property investors

Shire says Hunter syndrome treatment fails in key study

Reuters - UK Focus

Dec (Shanghai: 600875.SS - news) 19 (Reuters) - Shire Plc (Xetra: S7E.DE - news) 's investigational drug for treating pediatric patients with Hunter syndrome and cognitive impairment failed to meet the main goal of a late-stage trial.

The clinical trial evaluating SHP609, previously known as HGT-2310, did not meet either its primary or its key secondary endpoints, London-listed pharmaceutical firm said in a statement on Tuesday. (Reporting By Justin George Varghese in Bengaluru; Editing by Bernard Orr)